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To investigate the effects of electroacupuncture (EA) on serum FSH, E2, and LH levels, women with primary ovarian insufficiency
(POI) were treated with EA once a day, five times a week for the first four weeks and once every other day, three times a week, for
the following two months, and then were followed up for three months. Serum E2, FSH, and LH levels were measured at baseline,
at the end of treatment, and during followup. A total of 11 women with POI were included in this prospective consecutive case
series study. Compared with baseline, patients’ serum E2 increased, FSH decreased, and LH decreased (𝑃 = 0.002, 0.001, and 0.002,
resp.) after EA treatment, and these effects persisted during followup. With treatment, 10 patients resumed menstruation (10/11,
90.91%), whereas one patient remained amenorrhea. During followup, two patients, including the one with amenorrhea during
treatment, reported absence of menstruation. Temporary pain occurred occasionally, and no other adverse events were found
during treatment. The results suggest that EA could decrease serum FSH and LH levels and increase serum E2 level in women with
POI with little or no side effects; however, further randomized control trials are needed.

1. Introduction
Primary ovarian insufficiency (POI) is a syndrome characterized by amenorrhoea, sex steroid deficiency, and elevated gonadotrophins occurring in women under the age
of 40 years. Other terms describing the disease include
premature ovarian failure, premature menopause, and premature ovarian dysfunction. Clinical symptoms observed
are similar to those of menopause, which include hot
flashes, vaginal dryness, dyspareunia, insomnia, vaginitis,
and mood swings [1]; however, this condition differs from
menopause in its existence of varying and unpredictable
ovarian functions [2]. Rather than complete amenorrhea
in menopausal women, these patients may present with
intermittent and unpredictable menses. In addition, 5–10%
of women with POI will be able to conceive and deliver a
child after they have received the diagnosis [3]. Consequently,
a more accurate and informative term for this condition,

as indicated by Nelson [2], tends to be “primary ovarian
insufficiency.”
Formal diagnostic criteria of POI have not been established in any professional society; however, a commonly used
definition refers to the development of amenorrhoea for
four months or more due to cessation of ovarian function
before the age of 40 years [4]. The diagnosis is based on
elevated serum follicle-stimulating hormone (FSH) levels in
menopausal range (usually above 40 IU/L) detected on at
least two occasions with at least one month apart [5].
POI affects 1-2% of women younger than 40 years of age
and 0.1% of women younger than 30 years of age [6]. Significant impacts including psychosocial sequelae and major
health implications may result from POI. Long-term sequelae
of POI include significant increase in all-cause mortality and decreased life expectancy, increased cardiovascular
events, early onset of osteoporosis, increased risk of dementia
or decreased cognitive function, devastating psychological
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effects, sexual dysfunction, and infertility [7]. Given the significant impacts and long-term sequelae of POI on patients,
appropriate management is crucial in relieving symptoms
and improving quality of life. Besides daily intake of calcium
and vitamin D and management addressing emotional wellbeing, use of hormone (estrogen and progestin) replacement
therapy for young patients remains the major treatment [2].
However, not only evidence from randomized control trials is
still lacking regarding specific hormone replacement therapy
(HRT) regimen, but also the long-term risks of HRT in
women with POI are still unclear [8]. HRT in menopausal
women was found to be associated with increased risks
of breast cancer, heart attacks, and strokes [9]. Although
application of these results to young women with POI may
be invalid, similar risks may still exist in women with POI
receiving HRT.
Acupuncture, a major component of traditional Chinese
medicine, has been used in eastern Asian countries for
thousands of years for various symptoms that are or are
similar to those of menopause. With little to no side effects,
acupuncture has been found effective in relieving hot flashes
of bilaterally ovariectomized women [10], women with breast
cancer [11], and women undergoing perimenopause and
menopause [12]. In a recent published meta-analysis, Zheng
et al. [13] summarized several previously published metaanalyses and lots of clinical trials and found that acupuncture
could improve pregnancy outcomes in women undergoing in
vitro fertilization (IVF). In addition, for patients diagnosed
with polycystic cystic ovarian syndrome (PCOS), which is a
disorder characterized by anovulation resulting in irregular
menstruation, amenorrhea, infertility, and polycystic ovaries,
Lim et al. [14] found that acupuncture may be an inexpensive
effective intervention.
Although the therapeutic mechanisms of acupuncture in
the above-mentioned disorders are yet to be fully investigated, a plausible hypothesis may be that acupuncture can
modulate hypothalamic-pituitary-ovary axis (HPOA). Using
ovariectomized rats, Chen et al. [15] found that repeated
electroacupuncture (EA) increases serum E2 and reduces
LH; Zhao et al. [16] found that EA stimulates hypothalamic
aromatization which plays a key role in estrogen production
from androgen; Ma et al. [17] reported that EA decreased the
elevated estrogen receptor expression in hypothalamic preoptic area. This hypothesis is also concurred by the results from
two clinical trials in which acupuncture decreased LH and
increased E2 levels [10, 18]. Recent fMRI studies add further
credence to the hypothesis in which acupuncture was found
to modulate activities of the brain cortex including pituitary
and hypothalamus [19, 20]. Nonetheless, inconsistent results
were also found in other clinical trials. Dong et al. [21] found
that acupuncture could significantly improve menopausal
vasomotor symptoms but had no effects on serum FSH, LH,
and E2 levels in menopausal patients. EA was found effective
in the treatment of PCOS symptoms, but without significant
change in these hormone levels [22, 23].
Similar to menopause, infertility, and PCOS, POI is
also characterized by the dysfunction of HPOA. However,
to our best knowledge, no studies regarding acupuncture
effects on POI have been published in English; one study
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performed in China found positive results of acupuncture
on POI [24]. Nonetheless, the study had a small sample size,
lacked detailed documentation on hormone measurement,
acupuncture procedures, and methods used in the assessment
of efficacy [24]. In the present study, we aimed to investigate
the effects of acupuncture on serum FSH, E2, and LH levels
in women with POI. In addition, changes related to the
availability of menstruation were also reported.

2. Material and Methods
2.1. Study Design. This was a prospective consecutive case
series study performed at the Acupuncture Department of
Guang An Men Hospital, China Academy of Chinese Medical Sciences. The hospital ethics committee approved this
treatment protocol for women with POI, and patients signed
informed consent before study participation. Acupuncture
procedures were implemented by a senior acupuncturist with
more than 20 years’ clinical experience. Data management
and analysis were performed by graduates who were blinded
to the treatment procedures.
2.2. Participants. For inclusion, the following criteria had
to be fulfilled by the patients: amenorrhea for four months
or longer and FSH above 40 IU/L as detected on at least
two occasions with at least one month apart. Before treatment, all patients had gone through one month baseline
evaluation period during which they stopped all medications influencing reproductive hormones. These medications
include but are not limited to clomiphene, human chorionic gonadotropin (HCG), Letrozole, Premarin, and Provera
(Medroxyprogesterone Acetate). Patients were advised and
agreed not to use these medications during study.
2.3. Acupuncture Protocol. Hua Tuo brand needles (size
0.45 mm × 125 mm and 0.30 × 75 mm, manufactured by
Suzhou Medical Appliance, Suzhou, Jiangsu Province, China)
together with GB6805-2 Electro-Acu Stimulators (Medical
Supply & Equipment Co., Ltd, Shanghai, China) were used.
The parameters of electric stimulation were set as the following: continuous wave with electric current frequency of
20 Hz and intensity between 1 and 4 mA based on patients’
tolerance. Based on the clinical experiences of the acupuncturist, published research studies [15, 23, 24], and anatomical
knowledge (direct or indirect stimulation of T12-L2, S2-S4),
two EA prescriptions were used on patients alternatively.
Acupoint use in Prescription 1 consists of bilateral BL33, and
acupoints in Prescription 2 consist of CV4, bilateral ST25, and
bilateral ST29.
Acupoints were selected and localized according to WHO
Standardized Acupuncture Points Location [25]. Paired alligator clips with negative and positive electrodes of the EA
apparatus were attached to the needle holders at each pair
of the same acupoints on each side during treatment; no
electric stimulation was used at CV4. EA stimulation in
each treatment lasted 20 minutes. All patients received EA
treatment once a day, five times a week for the first four weeks,
once every other day, and three times a week for the following
two months. They were then followed up for three months.
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Needles of the size of 0.45 mm × 125 mm were inserted
obliquely into the bilateral third sacral foramina (BL33)
with a depth of 70–80 mm. Using 0.30 mm × 75 mm size
needles, needle insertion at bilateral ST25 was performed
perpendicularly with a depth of 45–55 mm. 0.30 mm×40 mm
size needles were inserted obliquely at CV4 and bilateral ST29
with a depth of 25 mm. Upon acupuncture at BL33, patients
should have a strong soreness sensation which radiates to
the lower abdomen. For acupuncture at ST25, CV4, and
ST29, needles should be inserted just deep enough to touch
the parietal peritoneum where the acupuncturist may feel
resistance under the needle tip and patients may have tingling
and twisting sensations.
2.4. Outcome Measures. At baseline of initial evaluation, the
dates of patients’ last menstrual cycle were documented, and
patients’ serum E2, FSH, and LH levels were measured. Based
on patients’ last menstrual cycle prior to study participation,
patients’ E2, FSH, and LH levels were measured on the 2nd–
4th day of the 1st menstrual cycle and on the 2nd–4th day
of the 4th menstrual cycle after cessation of EA treatment. In
addition, patients’ vaginal bleeding conditions were recorded
based on patients’ reports. Adverse events were documented
if available.
2.5. Statistical Analysis. Statistical analysis was performed
with the SPSS software package (Version 17.0) for Windows
XP. Quantitative data of serum E2, FSH, and LH levels were
expressed with mean ± SEM. Paired samples t-test was used
to measure the difference between values at baseline, at the
end of treatment, and during followup. A 5% significance
level (𝑃 < 0.05) and two-tailed tests were used for all tests.
Qualitative data including menstrual bleeding conditions and
adverse events during study were described.

3. Results
From February 2, 2010 to December 30, 2011, a total of 21
patients with POI, as diagnosed by department of gynecology
at tertiary-level hospitals in China, visited the Outpatient
Department of Acupuncture at the Guang An Men Hospital.
Of these patients, 10 were excluded from the study for the
following reasons: one patient did not meet the diagnostic
criteria of POI; eight had incomplete data although various
patient contacts had been made; one used estrogen medications during followup (Figure 1). Of the included 11 patients,
four were 25 to 30 years old, three were 31 to 35 years old,
and four were 36 to 39 years old. The shortest history of
amenorrhea was four months, and the longest was 10 years.
3.1. Hormone Levels (Tables 1 and 2). During the one month
baseline evaluation period, patients’ serum E2, FSH, and LH
values were 33.35 ± 10.83 pmol/L, 89.08 ± 11.97 IU/L, and
37.10 ± 3.47 IU/L, respectively. Serum E2 level increased to
223.82 ± 45.95 pmol/L after EA treatment and was maintained with a value of 217.53 ± 63.39 pmol/L during followup.
Patients’ serum FSH level decreased to 45.37 ± 7.07 IU/L after
EA treatment and was maintained at 49.28 ± 8.85 IU/L during followup. Patients’ serum LH level decreased to 22.08 ±
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Assessed for eligibility
(𝑛 = 21)

Excluded
(𝑛 = 10)
∙ Did not meet the diagnostic criteria (𝑛 = 1)
∙ Had incomplete data
(𝑛 = 8)
∙ Used estrogen medications during ( 𝑛 = 1)
followup

Patients accepted acupuncture treatment
(𝑛 = 11)
∙ Ages 25∼39 years old
∙ History of amenorrhea 4 months∼10 years

Figure 1: Flow chart of study participation.

3.66 IU/L after EA treatment and was maintained at 22.29 ±
4.42 IU/L during followup. Compared with baseline, patients’
serum E2 increased, FSH decreased, and LH decreased (𝑃 =
0.002, 0.001, and 0.002, resp.) after EA treatment, and these
results persisted during followup (𝑃 = 0.016 for E2, 0.005
for FSH, and 0.023 for LH as compared with baseline). No
difference was noticed in the hormone values between values
at the end of treatment and during followup (𝑃 > 0.05).
3.2. Symptoms. At baseline, all patients had had no periods
for more than four months and presented with varying
degrees of menopausal symptoms including hot flashes, night
sweats, vaginal dryness, and mood swings. With treatment,
10 patients resumed menstruation (10/11, 90.91%), whereas
one patient remained amenorrhea. Of the 10 patients who
regained menstruation, four patients had decreased menstrual flow but with normal color and duration as compared
with normal menstrual bleeding and six regained normal
duration, volume, and color of periods.
During followup, two patients reported amenorrhea
including the one with amenorrhea during treatment; four
patients maintained the normal menstrual cycle and flow; five
patients had irregular menstrual cycles. Of the 10 patients
who regained menstruation during treatment, their symptoms of night sweating, hot flashes, vaginal dryness, and
mood swings, if presented, were all alleviated during treatment. During followup, their symptoms remained largely
improved in six patients (6/10, 60%), but fluctuated in the
other four patients (4/10, 40%). In the one patient who had
had amenorrhea during the whole study, no obvious change
was observed in symptoms.
3.3. Adverse Events. In the present study, pain which is
considered normal occurred occasionally. The pain was
either instant upon needle insertion or well tolerated during
treatment and disappeared after needle removal. No other
adverse events were reported during study.
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Table 1: Demographic data and hormone values of patients during study.

Number

1
2
3
4
5
6
7
8
9
10
11

Age (y)

History of amenorrhea

39
32
30
30
31
37
32
27
38
39
28

4 years
4 months
3 years
10 years
7 years
1 year
5 years
15 months
4 months
2 years
1 year

Baseline
E2
FSH
pmol/L
IU/L
7.34
54.88
51.75
47.20
52.52
148.00
18.83
73.40
0.37
72.57
22.02
138.03
17.10
63.12
14.68
43.70
128.45
86.34
13.47
147.83
40.37
104.80

LH
IU/L
41.34
32.10
43.10
35.80
25.40
49.10
37.47
15.90
47.56
54.06
26.32

Hormone level
After treatment
E2
FSH
LH
pmol/L
IU/L
IU/L
418.38
23.30
19.33
319.29
9.40
2.30
29.36
89.10
26.19
90.14
70.23
26.83
253.23
46.90
15.40
232.31
63.30
37.83
374.34
27.04
15.4
18.35
48.00
13.09
407.37
24.90
45.48
264.24
42.10
15.01
55.05
54.80
26.05

E2
pmol/L
18.35
418.38
22.02
337.64
352.32
649.59
44.04
14.68
282.59
205.52
47.71

Followup
FSH
IU/L
59.29
5.00
89.00
5.50
29.30
37.20
63.60
57.90
36.70
67.83
90.80

LH
IU/L
4.12
2.10
18.00
10.94
16.02
18.24
38.38
23.68
43.20
26.07
44.47

E2: estradiol; FSH: follicle-stimulating hormone; LH: luteinizing hormone.

4. Discussion
In the present study, EA induced significant changes of
serum E2, FSH, and LH and the effects were maintained
during three-month followup when acupuncture treatment
was stopped. The FSH level dropped 43.71 ± 9.49 IU/L from
baseline to the end of treatment (𝑃 = 0.001) and the decrease
was still significant during the three-month followup with a
value of 39.80 ± 11.19 IU/L (𝑃 = 0.005 as compared with
baseline). E2 level increased 190.47±45.10 IU/L from baseline
to the end of treatment (𝑃 = 0.002) and the increase was
still significant during the three-month followup with a value
of 184.18 ± 63.47 IU/L (𝑃 = 0.016 as compared with
baseline). These results were similar to those report by Sha
et al. [24]. Using tailored cupping and moxibustion with
acupuncture therapy for patients with POI, Sha et al. [24]
found that FSH and E2 levels increased 30 days and 90
days after cessation of treatment whereas LH had no change
30 days but decreased significantly 90 days after cessation
of treatment. The slight difference may be due to date
difference of hormone measurements within the menstrual
cycle as Sha et al. [24] did not reported the time of hormone
measurement. Nonetheless, in the present study, 10 patients
resumed menstruation, and the majority (6/10) regained
normal period during treatment. The effects persisted in
the majority of patients during followup. The results of
the present study supported the gaining of menstruation in
a top athlete recently reported in a Japanese acupuncture
study [26]. In addition, improvements of other symptoms
including menstrual bleeding, night sweating, hot flashes,
vaginal dryness, and mood swing in the present study may
also indicate certain clinical effects of acupuncture for POI.
Modulation of FSH, E2, and LH levels may help explain
the mechanism of acupuncture for POI, which may be
similar to the use of acupuncture in other gynecological
disorders. Using acupuncture and auricular acupuncture,
Zhou et al. [10] found that acupuncture could significantly
increase serum E2 while decrease FSH and LH in bilaterally

ovariectomized Chinese women. Although patients’ exact
diagnoses vary, our results match the results reported by
Zhou et al. [10]. Patients included in the study by Zhou
et al. [10] were 41.6 ± 5.8 years old. By referring to the
diagnostic criteria of POI, we could infer that a great portion
of patients included in their study may also be diagnosed
with POI. Therefore, the results of the present research met
the expectation as deducted from the study by Zhou et al.
[10]. In addition, the results of the present study also support
the effects of acupuncture in the modulation of HPOA as
reported in rat studies [15–17].
Although measurement of sex hormones at a specific
date of the menstrual cycle seems illogical in rats, specific
measurement time of sex hormones during menstrual cycle
may be accounted for the hormone differences of acupuncture effects observed in other clinical trials [21–23]. In both
PCOS studies by Jadel et al. [22] and by Pastore et al. [23],
hormone levels were measured during the follicular phase
of the menstruation cycle when researchers did not find
significant changes in E2, FSH, and LH. However, in the
menopausal study, Dong et al. [21] found significant changes
in these reproductive hormones with acupuncture. Our study
confirmed the results reported by Dong et al. [21]. Although
patients’ diagnoses in these studies are different, PCOS,
menopause, and POI all are characterized by dysfunctions
of the HPOA and share similar physiological changes and
similar clinical presentations. This is true especially for
menopause and POI, and the present study of POI showed
similar responses of acupuncture on reproductive hormone
regulation as the study of menopause [21]. Consequently, the
different results regarding reproductive hormone regulation
in the PCOS studies may be due to different diagnosis or
different hormone measurement time during the menstrual
cycle. As patients’ symptoms of PCOS were improved in
both studies [22, 23], the difference may be more likely due
to the later. Sex hormone was measured in the 2–4th day
of menstrual phase in the present study, but measured in
the follicular phase in the PCOS studies. In addition, the

After treatment (B)
223.82 ± 45.95
45.37 ± 7.07
22.08 ± 3.66

Baseline (A)

33.35 ± 10.83
89.08 ± 11.97
37.10 ± 3.47

𝑛

11
11
11

217.53 ± 63.39
49.28 ± 8.85
22.29 ± 4.42

Followup (C)

E2: estradiol; FSH: follicle-stimulating hormone; LH: luteinizing hormone.

Serum hormone
level
E2 (pmol/L)
FSH (IU/L)
LH (IU/L)
AB
190.47 ± 45.10
43.71 ± 9.49
15.02 ± 3.70

Difference 𝑥 ± 𝑠
AC
184.18 ± 63.47
39.80 ± 11.19
14.81 ± 5.52
BC
6.29 ± 70.25
3.91 ± 9.47
0.21 ± 4.31

Table 2: Serum E2, FSH, and LH values assessed during study (mean ± SEM).
AB
−4.223
4.606
4.057

𝑡 value
AC
−2.902
3.557
2.683

BC
0.09
−0.413
−0.049

AB
0.002
0.001
0.002

𝑃 value
AC
BC
0.016 >0.05
0.005 >0.05
0.023 >0.05
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results of acupuncture on menstruation and gynecological
symptoms in the present study partially confirmed the therapeutic effects of acupuncture on gynecological symptoms.
Therefore, we should believe that acupuncture could restore
the normal function of hypothalamus-pituitary-ovary axis
(HPOA) in body.
Besides the HPOA hypothesis, modulation of autonomic
nerve function is also proposed as the reason of acupuncture
effects on gynecological disorders [27, 28]. Acupuncture
stimulation to the sacral segment was found to change the
vigilance state of animals via GABAergic systems suppressing
the activity of noradrenergic LC neurons [27]. In the study
by Wang et al. [28], researchers found that acupuncture
could enhance vagal activities and suppress sympathetic
activities. Based on anatomical knowledge, acupuncture at
BL33 stimulates sacral nerves, part of which form the pelvic
nerve and other autonomic nerve structures innervating deep
organs inside the lower abdominal areas. Thus, reproductive
hormone modulation effects in the present study may also be
caused by the effects of acupuncture in the autonomic system.
In addition, Stener-Victorin et al. [29] found that lowfrequency (2 Hz) EA stimulation with a strong intensity
(6 mA) increases ovarian blood flow. The visceral peritoneum
is supplied by branches from somatic efferent and afferent
nerves that also supply the muscles and skin, respectively.
Acupuncture deep into the parietal peritoneum at CV4, ST25,
and ST29 of the present study may thus provide stimulations
to the abdominal muscles and the surrounding structures and
thus modulate their function and improve blood circulation
inside the lower abdomen. EA stimulation parameters of
20 Hz and 1 to 4 mA based on patients’ tolerance were used
in the present study. As 20 Hz is significantly different from
the high frequency EA (80 Hz) used in the study by StenerVictorin et al. [29] and largest tolerant EA intensity in patients
can be considered as a strong intensity, the positive results of
the present study may thus partially support that middle to
low-frequency EA stimulation with strong intensity may be
the optimal stimulation parameters for EA treatment [29].
4.1. Limitations. Nonetheless, this study only included 11
patients at only one tertiary level hospital in China; therefore,
the result of this study may not well characterize the general response of women with POI undergoing acupuncture
treatments. Although the significant changes of sex hormones
in the present study were most likely due to acupuncture
effects; it may also be partially due to the typical disease
course of POI as 5–10% of women with POI will be able
to conceive and deliver a child after they have received the
diagnosis [3]. With an open label prospective study design
and no control group, researcher could not eliminate these
cofounding factors. Furthermore, signs and symptoms of POI
were subjectively reported by patients and documented by
researchers rather than objectively measured with standard
questionnaires and statistically analyzed. These may cause
bias in the data management and documentation. Although
EA at ST25, CV4, and ST29 using stimulation of 20 Hz
and 1 to 4 mA based on patients’ tolerance were applied in
the present study, the optimal EA treatment regime with
appropriate stimulations remains to be established. To test the
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therapeutic effectiveness of acupuncture, further randomized
control trials are needed.

5. Conclusion
The present study demonstrated that EA could decrease
serum FSH and LH levels, increase serum E2 level, and help
regain menstruation in women with POI with little or no
side effects; however, further randomized control trials are
needed.
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